Before listing, the company’s shares traded at a Rs 360 premium in the grey market. It raised Rs 582 crore from anchor investors, including HDFC MF, ICICI Pru MF, SBI MF, Abu Dhabi Investment Authority, Goldman Sachs Asset Management, Nomura, and HDFC Life. Analysts are bullish on the IPO for listing gains and long-term growth, citing its strong position in domestic therapeutics and expansion plans in India and exports.
| Subscribe To Our Free Newsletter |
